Pharmaceutical Switzerland-headquartered Nycomed says it welcomes the decision by the Scottish Medicines Consortium (SMC) on Instanyl, (intranasal fentanyl), the only fast-acting intranasal treatment licensed for breakthrough cancer pain. The SMC decision means that cancer patients in Scotland will now have another option for the treatment of breakthrough cancer pain within the National Health Service in Scotland, the privately-owned drugmaker notes. 10 November 2009